7,605.76

-114.63

-1.48%

51,995.26

-347.30

-0.66%

25,552.02

-632.71

-2.42%

2,818.21

-41.01

-1.43%

4.9290

-0.0600

-1.20%

19.57

+2.37

+13.81%

3,911.90

-119.50

-2.96%

76,565.84

-4,524.22

-5.58%

Crude Oil Dec 26

104.51

+2.51

+2.46%

US Private Equity

10,932.82

-7.68

-0.07%

We are experiencing some temporary issues. The market data on this page is currently delayed.

Nasdaq - Delayed Quote USD

BlackRock Health Sciences Opps Svc (SHISX)

69.09 +1.60 (+2.37%)

As of 8:07:35 AM EDT. Market Open.

Chart Range Bar

AlphaSpace Chart

Loading chart for SHISX

Previous Close 67.49
YTD Return 10.02%
Expense Ratio 1.16%
Category Health
Last Cap Gain 49.00
Morningstar Rating
★ ★ ★ ★ ★
Morningstar Risk Rating Average
Net Assets 6.26B
Beta (5Y Monthly) 0.52
Yield 0.22%
5y Average Return --
Holdings Turnover 49.00%
Last Dividend 0.16
Inception Date Oct 16, 2000

The fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. It will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries.

BlackRock

Fund Family

Health

Fund Category

6.26B

Net Assets

2000-10-16

Inception Date

Trailing returns as of 10/27/2026. Category is Health.

YTD Return

SHISX

10.02%

Category

7.95%

1-Year Return

SHISX

22.96%

Category

30.16%

3-Year Return

SHISX

11.87%

Category

16.10%

5-Year Return

SHISX

6.54%

Category

15.71%

SHSKX BlackRock Health Sciences Opps K

75.72 +2.37%

BHSRX BlackRock Health Sciences Opps R

65.26 +2.38%

SHSCX BlackRock Health Sciences Opps Inv C

51.04 +2.37%

SHSSX BlackRock Health Sciences Opps Instl

75.47 +2.37%

BSTSX BlackRock Technology Opportunities Svc

83.02 -2.15%

Global Fetal Aneuploidy Confirmation Testing Market Report 2026 | Capitalize on 10.6% CAGR to $2.36 Billion by 2030 with Thermo Fisher, Labcorp, Quest Diagnostics and Illumina

Global Fetal Aneuploidy Confirmation Testing Market Report 2026 | Capitalize on 10.6% CAGR to $2.36 Billion by 2030 with Thermo Fisher, Labcorp, Quest Diagnostics and Illumina

4 Dividend Kings With 50-Plus Years of Payout Increases for Retirement Income

4 Dividend Kings With 50-Plus Years of Payout Increases for Retirement Income

Global Gene Panel Reconciliation Services Market Report 2026 | Capitalize on AI-Driven Genomics as Roche, Thermo Fisher, Illumina and QIAGEN Accelerate a $2.38B Market by 2030

Global Gene Panel Reconciliation Services Market Report 2026 | Capitalize on AI-Driven Genomics as Roche, Thermo Fisher, Illumina and QIAGEN Accelerate a $2.38B Market by 2030

How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade

How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade

What Does Gilead Sciences (GILD) Gain From Its Canada Deal And $45 Million Settlement?

What Does Gilead Sciences (GILD) Gain From Its Canada Deal And $45 Million Settlement?

AbbVie (NYSE:ABBV) posts Q3 2026 sales in line with estimates

AbbVie (NYSE:ABBV) posts Q3 2026 sales in line with estimates

Eli Lilly Stock Rose Nearly 7% to a Record as It Lifted Its 2026 Sales Forecast to as Much as $92 Billion. Here’s Where the Stock Could Go

Eli Lilly Stock Rose Nearly 7% to a Record as It Lifted Its 2026 Sales Forecast to as Much as $92 Billion. Here’s Where the Stock Could Go

Here's What Key Metrics Tell Us About AbbVie (ABBV) Q3 Earnings

Here's What Key Metrics Tell Us About AbbVie (ABBV) Q3 Earnings

Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook

Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook

GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks

GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks

LLY Q3 Earnings Call Highlights Raised Outlook and Obesity Drug Growth

LLY Q3 Earnings Call Highlights Raised Outlook and Obesity Drug Growth

FSDAX Fidelity Select Defense & Aerospace

25.63 +4.06%

FPHAX Fidelity Select Pharmaceuticals Port

37.58 +3.13%

FSHOX Fidelity Select Construction & Housing

115.33 +2.67%

BREUX Baron Real Estate R6

38.71 +2.62%

BREFX Baron Real Estate Retail

37.47 +2.60%

BREIX Baron Real Estate Institutional

38.71 +2.60%

VSCRX Virtus KAR Small-Cap Core R6

52.00 +2.56%

PKSAX Virtus KAR Small-Cap Core A

46.44 +2.56%

PKSFX Virtus KAR Small-Cap Core I

51.67 +2.56%

PHLAX PGIM Jennison Health Sciences A

39.83 +2.42%

PHSZX PGIM Jennison Health Sciences Z

52.82 +2.40%

PHLQX PGIM Jennison Health Sciences R6

53.45 +2.39%

BHSRX BlackRock Health Sciences Opps R

65.26 +2.38%

PJHRX PGIM Jennison Health Sciences R

36.10 +2.38%

SHSSX BlackRock Health Sciences Opps Instl

75.47 +2.37%

SHSAX BlackRock Health Sciences Opps Inv A

68.64 +2.37%

Mobilize your Website

View Site in Mobile | Classic

Share by: